Curated News
By: NewsRamp Editorial Staff
November 02, 2026
HeartBeam's Portable ECG Shows Promise in Heart Attack Detection
TLDR
- HeartBeam's portable ECG achieved 81.8% specificity versus 71.4% for standard ECGs, giving it a competitive edge in heart attack assessment.
- The ALIGN-ACS study enrolled 132 adults and compared HeartBeam's cable-free 3D ECG with standard 12-lead ECGs, showing higher specificity and comparable sensitivity.
- HeartBeam's user-friendly ECG technology could enable faster, remote heart attack detection, improving access to life-saving care for people everywhere.
- All 132 participants recorded their own ECGs without prior training, highlighting the simplicity of HeartBeam's portable, cable-free design.
Impact - Why it Matters
This news matters because HeartBeam's portable, cable-free ECG technology could revolutionize cardiac care by enabling patients to record clinical-grade ECGs anytime, anywhere, without training. With higher specificity than standard ECGs, it may reduce false positives and unnecessary hospital visits, while comparable sensitivity ensures reliable detection of serious conditions like STEMI. The technology's potential for remote assessment could lead to faster diagnosis and treatment, especially in underserved or rural areas, and empower patients to take an active role in their heart health. If approved, it would provide a convenient, non-invasive tool for early heart attack detection, potentially saving lives and reducing healthcare costs.
Summary
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac monitoring, has announced positive results from its ALIGN-ACS pilot study, which evaluates the HeartBeam System for heart attack assessment. The findings were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego. The study enrolled 132 adults and compared HeartBeam’s portable, cable-free electrocardiogram (ECG) technology with standard 12-lead ECGs in assessing acute coronary syndrome (ACS). Notably, HeartBeam demonstrated higher specificity than conventional ECGs (81.8% versus 71.4%) and comparable sensitivity (60.2% versus 63.0%). For ST-elevation myocardial infarction (STEMI), sensitivity was 82.9% for HeartBeam compared with 83.8% for standard ECGs. All participants successfully recorded their own ECGs under clinical supervision without prior training, underscoring the device’s ease of use.
The study also revealed greater consistency among cardiologists interpreting HeartBeam recordings compared with standard ECGs, supporting the technology’s potential for remote cardiac assessment. HeartBeam plans to leverage these findings to inform a U.S. pivotal study expected to begin in the first quarter of 2027, with the goal of supporting a future Food and Drug Administration (FDA) submission to expand the system’s indication beyond arrhythmia assessment to include heart attack assessment. Although HeartBeam’s heart attack assessment technology has received FDA Breakthrough Device Designation, it remains investigational and is not currently FDA-cleared for heart attack assessment. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software was cleared in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam's Portable ECG Shows Promise in Heart Attack Detection
